Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking
This week on "The Readout LOUD" podcast": Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what's next in pain medicine?
Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.
What's Your Reaction?
